21 results about "Stem cell factor" patented technology

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The present application provides novel anti-TSLP and anti-SCF antibodies, and binding domains thereof, as well as bispecific constructs comprising such antibodies and binding domains. The present application also provides treatment of immune response (e.g., immune response) via interaction (e.g., binding) of TSLP and / or SCF with its receptors (e.g., TSLPR and / or c-Kit, respectively) on immune cells by administering to a patient in need thereof the antibodies (or antigen binding fragments thereof), bispecific constructs or compositions described herein, or compositions. Immune cell migration, activation and / or proliferation) related disorders, such as disorders of the immune system.

The invention relates to the field of medicines, in particular to a stem cell factor composite medicine composition for treating allergic dermatitis and a preparation method thereof. The composite pharmaceutical composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of stem cell factors, 2 to 6 parts of agilawood extract, 1 to 3 parts of forskolin and 0.1 to 0.3 part of stabilizer. The pharmaceutical composition can effectively inhibit bacteria, relieve pain and relieve itching, and can remarkably relieve itching and inflammation caused by allergic dermatitis by inhibiting release of inflammatory factors.

A hematopoietic stem cell (HSC) proliferation medium includes a basal medium, 0.1 ng / mL to 200.0 ng / mL of thrombopoietin (TPO), 0.1 ng / mL to 200.0 ng / mL of stem cell factor (SCF), 0.1 ng / mL to 20.0 ng / mL of interleukin-3 (IL-3), 0.1 ng / mL to 100.0 ng / mL of interleukin-6 (IL-6), 0.1 ng / mL to 200.0 ng / mL of Flt-3 ligand (FL), 0.1 μg / mL to 20.0 μg / mL of insulin, 0.1 μg / mL to 120.0 μg / mL of transferrin, 0.1 g / L to 3.0 g / L of human serum albumin (HSA), 0.1 μM to 4.0 μM of pyrimido-indole derivative UM729, and 0.1 μM to 2.0 μM of aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Methods for in vitro proliferation of hematopoietic stem cells (HSCs) and in vitro production of hematopoietic progenitor cells (HPCs) using the HSC proliferation medium are also provided.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

A nasal allergen blocking agent. Specifically, the present invention relates to a preparation method for an allergen blocking agent loaded with an umbilical cord mesenchymal stem cell culture medium extract. The provided allergen blocking agent is prepared from the following raw materials: lyophilized powders of the umbilical cord mesenchymal stem cell culture medium extract, hydroxypropyl methylcellulose, a honeysuckle extract, and borneol. By means of adding the honeysuckle extract and the umbilical cord mesenchymal stem cell culture medium extract to the allergen blocking agent, under the interaction of various raw materials, capillary permeability can be reduced by means of dilating capillaries, thereby reducing tissue fluid exudation, helping reduce swelling, inhibiting smooth muscle contraction, alleviating the spasticity in the respiratory tract and other parts, and improving related discomfort symptoms. The dry powder mixture is loaded into a nasal spray reagent bottle for use. The anti-allergen blocking agent can not only physically isolate allergens, but also load a variety of stem cell factors contained in the umbilical cord mesenchymal stem cell culture medium extract, thereby eliminating chronic nasal mucosa inflammation, repairing nasal mucosa damage without any toxic and side effects, and effectively resisting the onset of allergic rhinitis.

The present disclosure provides immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NSG TM ) mouse models comprising an inactivated mouse Flt3 allele, a nucleic acid encoding human interleukin 3 (IL3), a nucleic acid encoding human granulocyte / macrophage stimulating factor (GM-CSF), a nucleic acid encoding human stem cell factor (SCF), and an HLA-A2 / H2-D / B2M transgene encoding (i) human B2 microglobulin (B2M) covalently linked to the MHC class I, alpha 1 and alpha 2 binding domains of the human HLA-A2.1 gene and (ii) the alpha 3 cytoplasmic and transmembrane domains of murine H2-Db.

The disclosure relates to methods for treating atopic dermatitis with an antibody that binds to stem cell factor 248 (SCF248).

The invention discloses a targeted delivery preparation as well as a preparation method and application thereof, and belongs to the technical field of biology and new medicine. The targeted delivery preparation comprises an agent A and an agent B in a ratio of (0.1-0.3) g: (2-5) mL; the agent A comprises nasal brain targeting peptide modified stem cell factor liposome freeze-dried powder and gel dry powder, the amino acid sequence of the nasal brain targeting peptide is as shown in SEQ ID NO.1, and the gel dry powder is formed by self-crosslinking mangiferin and rutin; and the agent B is a normal saline solution containing carboxymethyl chitosan. The targeted delivery preparation not only can meet long-time stable storage, but also can enhance the nasal-brain delivery efficiency of stem cell drugs. Besides, the targeted delivery preparation can be used independently or in combination with other treatment drugs, and is used for treating ischemic cerebral diseases, especially cerebral arterial thrombosis.

The present disclosure describes methods of generating a transgenic cell or mouse that expresses a chimeric c-KIT protein capable of expression on mouse cells and binding to mouse stem cell factor (SCF) which can be inhibited by anti-human c-KIT inhibitors. The transgenic cells and mice can be used to test candidate anti-human c-KIT inhibitors.

The invention relates to the technical field of cell therapy. The invention provides a culture medium composition for culturing CIK (cytokine-induced killer) cells and a use method thereof. The culture medium composition comprises an inoculation culture medium and a supplementary reagent, the inoculation culture medium is based on a serum-free culture medium, and further comprises a CD3 monoclonal antibody, interleukin-15, a stem cell factor, a granulocyte colony stimulating factor and an FLT3 ligand; and the supplementary reagent is interleukin-2. According to the culture medium disclosed by the invention, the amplification amount of CIK cells is remarkably increased through the synergistic effect of all the components; the proportion and concentration of each factor are optimized, and side effects caused by excessive use of a single factor are avoided; the culture conditions are simple and feasible and are suitable for large-scale preparation. The CIK cells cultured by using the culture medium disclosed by the invention are high in purity and good in morphology, the survival rate of the CIK cells can be kept at 93-95%, and the purity of CD3 + CD56 + is 30-50%.

To provide anti-stem cell factor antibodies and methods of use thereof in renal diseases.SOLUTION: The disclosure relates to methods of use in renal diseases and disorders of antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248 and are useful for treating inflammatory and fibrotic renal disorders. In one aspect, the disclosure provides a method for treating renal diseases or disorders, comprising administering to a patient having a renal disease or disorder an antibody or a fragment thereof that specifically binds to Stem Cell Factor (SCF).SELECTED DRAWING: None

The application provides a medicine umbilical cord mesenchymal stem cell factor and a preparation method thereof, belongs to the biotechnology field, and the preparation method comprises the following steps: inducing and culturing the third generation of expanded cells of umbilical cord mesenchymal stem cells, the induction culture medium contains epidermal growth factor, vascular endothelial growth factor, deferoxamine, vitamin C, rapamycin, asiaticoside, astragaloside IV, astragalus polysaccharide and the like, the secretion of the target factor is effectively promoted, cell differentiation is controlled, two kinds of chromatography columns are used for purification and extraction, the product yield is high, the purity is high, and the efficacy of the product is further improved.

The invention provides a culture medium for inducing secretion of stem cell factors and application of the culture medium, and belongs to the technical field of cell biology. The culture medium adopts a three-stage dynamic induction strategy and comprises a starting culture medium (containing CHIR99021 and valproic acid), an induction culture medium (containing Forskolin, SR3677 and melatonin) and a maintenance amplification culture medium (containing ISX-9 and resveratrol). Through staged and accurate small molecule stimulation, the paracrine function of the cord blood mesenchymal stem cells can be efficiently and synergistically enhanced, and the secretion level of multiple therapeutic factors such as SCF, VEGF, HGF and IGF-1 is remarkably improved. Therefore, the invention provides a safe and stable culture system with definite components, the culture system is used for obtaining a high-activity stem cell secretion product, and the product can be applied to preparation of an external gel preparation for promoting skin wound healing and has important clinical transformation value.

The application discloses application of a soybean nuclear stem cell factor coding gene GmNSN1. The application of the soybean nuclear stem cell factor coding gene GmNSN1 shown in SEQ ID NO. 1 in genetic engineering modification of soybean resistance to Spodoptera litura is disclosed. Mutating the gene can significantly improve the resistance of soybean to Spodoptera litura. The soybean nuclear stem cell factor coding gene GmNSN1 can be transformed into soybean by constructing a gene editing vector and genetically engineering, the GmNSN1 gene is directionally mutated, and the resistance of soybean to Spodoptera litura is regulated.

The invention discloses an adeno-associated virus AAV vector. The adeno-associated virus AAV vector comprises a cytokine gene, the cell factor is selected from any one or more than two of the following components: human interleukin 2 (IL2), human interleukin 3 (IL3), human interleukin 6 (IL6), human interleukin 15 (IL15), human thrombopoietin (THPO), human stem cell factor (SCF) and human granulocyte-macrophage colony stimulating factor (GM-CSF). The invention also discloses an AAV vector combination comprising any two or more than three AAV vectors mentioned above. The invention also discloses an application of the AAV vector and a combination of the AAV vector in construction of immune system humanized non-human animals. The invention further discloses a method for constructing the immune system humanized non-human animal.

Provided is a method of inducing the proliferation and / or differentiation of induced pluripotent cells, embryonic stem cells, hematopoietic stem / progenitor cells and megakaryocytes into platelets, comprising culturing cells with a culture medium containing TPO (thrombopoietin), a SCF (stem cell factor), Flt3 (Fms-related tyrosine kinase 3 ligand), IL-3 (interleukin-3), IL-6 (interleukin-6), an AHR antagonist and PVA (polyvinyl alcohol). Also provided are a culture medium for inducing cell proliferation and / or differentiation into platelets, a composition, a culture platform and the use thereof.

The invention provides a method for generating hematopoietic stem cells or hematopoietic progenitor cells in vitro and application of the hematopoietic stem cells or hematopoietic progenitor cells, and the method comprises the following steps: inducing endothelial cells from placenta and / or embryo to obtain the hematopoietic stem cells or hematopoietic progenitor According to the application, the placenta or embryo-derived hematopoietic endothelial cells are induced into hematopoietic stem cells or hematopoietic progenitor cells for the first time, so that the aim of turning waste into wealth is And in the process of inducing the hematopoietic stem cells or hematopoietic progenitor cells, only two cell factors, namely the fibroblast growth factor 2 and the stem cell factor, are used, so that the composition of the culture medium is simplified.

The invention discloses a goose primordial germ cell separation culture medium and application, and belongs to the technical field of biology. The culture method comprises the following steps: adding a B-27 supplement, glutamine dipeptide, non-essential amino acid, nucleoside, beta-mercaptoethanol, ovalbumin, pyruvic acid, calcium chloride, heparin sodium, an insulin-like growth factor 1, a fibroblast growth factor 2, a bone forming protein 4, a stem cell factor and a leukemia inhibition factor into a calcium-free DMEM culture medium with the glucose concentration of 12mM; the conditions of small quantity, large differentiation and difficulty in long-term maintenance of primordial germ cells during preparation can be effectively avoided, and the method is more stable and efficient. Primordial germ cells prepared by using the culture medium still have good chimeric goose embryo production performance after cryopreservation, the maximum survival rate of 16-day pregnant embryos can reach 57%, and meanwhile, chimeric gooses have normal reproductive capacity and can be used for improved variety propagation and cross breeding; in addition, the prepared primordial germ cells still have the same level of cell performance after gene editing, and can be used for gene editing goose production.